| Drug General Information |
| Drug ID |
D0F2ML
|
| Former ID |
DNC004594
|
| Drug Name |
MEDETOMIDINE
|
| Drug Type |
Small molecular drug
|
| Indication |
Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]
|
Phase 2 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H32N4
|
| Canonical SMILES |
CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C
|
| InChI |
1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)
|
| InChIKey |
CUHVIMMYOGQXCV-UHFFFAOYSA-N
|
| CAS Number |
CAS 113775-47-6
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| Alpha-1B adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
| Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
| Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04020:Calcium signaling pathway
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
AMPK signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Vitamin D Receptor Pathway
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
AMPK SignalingWP58:Monoamine GPCRs
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Endothelin Pathways
|
| References |
| REF 1 | Sedative and cardiopulmonary effects of medetomidine hydrochloride and xylazine hydrochloride and their reversal with atipamezole hydrochloride in calves. Am J Vet Res. 2008 Mar;69(3):319-29. |
|---|
| REF 2 | J Med Chem. 1994 Jul 22;37(15):2328-33.A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic receptors. |
|---|
